Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Generic drugs. Therapeutic equivalence.

Meredith PA.

Drug Saf. 1996 Oct;15(4):233-42. Review.

PMID:
8905248
2.

Rational use of generic psychotropic drugs.

Carbon M, Correll CU.

CNS Drugs. 2013 May;27(5):353-65. doi: 10.1007/s40263-013-0045-2. Review.

PMID:
23620145
3.

[Generic drugs: quality, efficacy, safety and interchangeability].

Tschabitscher D, Platzer P, Baumgärtel C, Müllner M.

Wien Klin Wochenschr. 2008;120(3-4):63-9. doi: 10.1007/s00508-008-0927-3. German.

PMID:
18322766
4.
5.

Pharmaceutical equivalence by design for generic drugs: modified-release products.

Raw AS, Lionberger R, Yu LX.

Pharm Res. 2011 Jul;28(7):1445-53. doi: 10.1007/s11095-011-0397-6. Epub 2011 Mar 9.

PMID:
21387150
6.

Bioequivalence requirements for generic products.

Nation RL, Sansom LN.

Pharmacol Ther. 1994 Apr-May;62(1-2):41-55. Review.

PMID:
7991647
7.

Potential concerns about generic substitution: bioequivalence versus therapeutic equivalence of different amlodipine salt forms.

Meredith PA.

Curr Med Res Opin. 2009 Sep;25(9):2179-89. doi: 10.1185/03007990903116867. Review.

PMID:
19601710
8.

[Bioequivalence studies of pharmaceutical preparations].

Vetchý D, Frýbortová K, Rabisková M, Danecková H.

Cas Lek Cesk. 2007;146(5):431-3. Review. Czech.

PMID:
17554963
9.

Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.

Feng L, Shen-Tu J, Liu J, Chen J, Wu L, Huang M.

Clin Ther. 2009 Jul;31(7):1559-67. doi: 10.1016/j.clinthera.2009.07.017.

PMID:
19695405
10.

International harmonization of bioequivalence studies and issues shared in common.

Nakai K, Fujita M, Ogata H.

Yakugaku Zasshi. 2000 Nov;120(11):1193-200.

PMID:
11190204
11.

Bioequivalence and other unresolved issues in generic drug substitution.

Meredith P.

Clin Ther. 2003 Nov;25(11):2875-90.

PMID:
14693311
12.

Bioequivalence of single 100-mg doses of two oral formulations of topiramate: an open-label, randomized-sequence, two-period crossover study in healthy adult male Mexican volunteers.

Piñeyro-López A, Piñeyro-Garza E, Gómez-Silva M, Reyes-Araiza R, Flores-Diego MA, Borrego-Alvarado S, Gamino-Peña ME, Vargas-Zapata R, Salazar-Leal ME.

Clin Ther. 2009 Feb;31(2):411-7. doi: 10.1016/j.clinthera.2009.02.001.

PMID:
19302913
13.

Lack of pharmacokinetic bioequivalence between generic and branded amoxicillin formulations. A post-marketing clinical study on healthy volunteers.

Del Tacca M, Pasqualetti G, Di Paolo A, Virdis A, Massimetti G, Gori G, Versari D, Taddei S, Blandizzi C.

Br J Clin Pharmacol. 2009 Jul;68(1):34-42. doi: 10.1111/j.1365-2125.2009.03399.x.

14.

Current status of the international comparator (reference) product system.

Idänpään-Heikkilä JE.

Eur J Drug Metab Pharmacokinet. 2000 Jan-Mar;25(1):36-7.

PMID:
11032088
15.

Pharmacokinetics and bioequivalence study of three oral formulations of valsartan 160 mg: a single-dose, randomized, open-label, three-period crossover comparison in healthy Indian male volunteers.

Iqbal M, Khuroo A, Batolar LS, Tandon M, Monif T, Sharma PL.

Clin Ther. 2010 Mar;32(3):588-96. doi: 10.1016/j.clinthera.2010.03.004.

PMID:
20399995
16.

Relative bioavailability and pharmacokinetic properties of two different enteric formulations of esomeprazole in healthy Bangladeshi male volunteers: An open-label, single-dose, randomized-sequence, two-way crossover study.

Ullah MA, Shams-Ud-Dowla, Maruf AA, Azad MA, Shohag MH, Sultana R, Latif AH, Hasnat A.

Clin Ther. 2010 Jul;32(7):1419-26. doi: 10.1016/j.clinthera.2010.07.007.

PMID:
20678688
17.
18.

Quality of reporting of bioequivalence trials comparing generic to brand name drugs: a methodological systematic review.

van der Meersch A, Dechartres A, Ravaud P.

PLoS One. 2011;6(8):e23611. doi: 10.1371/journal.pone.0023611. Epub 2011 Aug 17. Review.

19.

Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.

Davit BM, Nwakama PE, Buehler GJ, Conner DP, Haidar SH, Patel DT, Yang Y, Yu LX, Woodcock J.

Ann Pharmacother. 2009 Oct;43(10):1583-97. doi: 10.1345/aph.1M141. Epub 2009 Sep 23.

PMID:
19776300
20.

Results of a single-center, single-dose, randomized-sequence, open-label, two-way crossover bioequivalence study of two formulations of valsartan 160-mg tablets in healthy volunteers under fasting conditions.

Spínola AC, Almeida S, Filipe A, Neves R, Trabelsi F, Farré A.

Clin Ther. 2009 Sep;31(9):1992-2001. doi: 10.1016/j.clinthera.2009.09.002.

PMID:
19843489

Supplemental Content

Support Center